Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes
The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 [plusmn] 7.4) year...
Gespeichert in:
| Veröffentlicht in: | Metabolism, clinical and experimental clinical and experimental, 2002-03, Vol.51 (3), p.314-317 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 317 |
|---|---|
| container_issue | 3 |
| container_start_page | 314 |
| container_title | Metabolism, clinical and experimental |
| container_volume | 51 |
| creator | Hirose, Hiroshi Kawai, Toshihide Yamamoto, Yukihiro Taniyama, Matsuo Tomita, Motowo Matsubara, Koichi Okazaki, Yasunori Ishii, Tatsuya Oguma, Yuko Takei, Izumi Saruta, Takao |
| description | The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 [plusmn] 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 [plusmn] 14 to 101 [plusmn] 10 mm Hg), FPG (8.6 [plusmn] 1.4 to 7.0 [plusmn] 1.0 mmol/L), serum insulin (54 [plusmn] 11 to 30 [plusmn] 8 pmol/L, P [lt ] .01 for all), and HbA1c (6.7 [plusmn] 0.8 to 6.1% [plusmn] 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 [plusmn] 3.2 to 27.0 [plusmn] 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 [plusmn] 24 to 138 [plusmn] 24 mg/dL) and SAT (155 [plusmn] 69 to 179 [plusmn] 81cm2, P [lt ] .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 [plusmn] 1.7 to 14.4 [plusmn] 2.1 [mu ]g/mL, P = .005). VAT tended to increase (165 [plusmn] 38 to 180 [plusmn] 46 cm2) and VAT/SAT ratio tended to decrease (1.2 [plusmn] 0.3 to 1.1 [plusmn] 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level. |
| doi_str_mv | 10.1053/meta.2002.30506 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71509059</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026049502174385</els_id><sourcerecordid>71509059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-ca412a2279fb205235fd0bf10db06620fa37a50d2db5b864a0b67ab4d385824e3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhi0EokvhzA35AqdmO7HjfBxRVb5UiQuco7E9BqMkDrZTtPwN_jBedqWeONkePX5m9A5jL2vY16Dk9UwZ9wJA7CUoaB-xXa2kqPoW4DHblXpbQTOoC_YspR8A0HV9-5Rd1HXfd3Xb7tifW-fI5MSD46sP3yaf8XdYiIeFH-U6TN7wFSOWF8V0xXWwB-4wc-tTjl5v2YfliuNieaK4zRytX4vBZL_wie5pSrzcPuGKCyXiM05UhNnTUtr-8vk7z4eVuChC1KVJes6eOJwSvTifl-zru9svNx-qu8_vP968vauM7GSuDDa1QCG6wWkBSkjlLGhXg9XQtgIcyg4VWGG10n3bIOi2Q91Y2ateNCQv2ZuTd43h50Ypj7NPhqapDBq2NHa1ggHUUMDrE2hiSCmSG9foZ4yHsYbxuIfxGNV43MP4bw_lx6uzetMz2Qf-HHwBXp8BTAYnF3ExPj1wUslGQle44cSVGOneUxyTKckZsj6WiEcb_H-H-AsK9Kaq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71509059</pqid></control><display><type>article</type><title>Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Hirose, Hiroshi ; Kawai, Toshihide ; Yamamoto, Yukihiro ; Taniyama, Matsuo ; Tomita, Motowo ; Matsubara, Koichi ; Okazaki, Yasunori ; Ishii, Tatsuya ; Oguma, Yuko ; Takei, Izumi ; Saruta, Takao</creator><creatorcontrib>Hirose, Hiroshi ; Kawai, Toshihide ; Yamamoto, Yukihiro ; Taniyama, Matsuo ; Tomita, Motowo ; Matsubara, Koichi ; Okazaki, Yasunori ; Ishii, Tatsuya ; Oguma, Yuko ; Takei, Izumi ; Saruta, Takao</creatorcontrib><description>The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 [plusmn] 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 [plusmn] 14 to 101 [plusmn] 10 mm Hg), FPG (8.6 [plusmn] 1.4 to 7.0 [plusmn] 1.0 mmol/L), serum insulin (54 [plusmn] 11 to 30 [plusmn] 8 pmol/L, P [lt ] .01 for all), and HbA1c (6.7 [plusmn] 0.8 to 6.1% [plusmn] 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 [plusmn] 3.2 to 27.0 [plusmn] 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 [plusmn] 24 to 138 [plusmn] 24 mg/dL) and SAT (155 [plusmn] 69 to 179 [plusmn] 81cm2, P [lt ] .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 [plusmn] 1.7 to 14.4 [plusmn] 2.1 [mu ]g/mL, P = .005). VAT tended to increase (165 [plusmn] 38 to 180 [plusmn] 46 cm2) and VAT/SAT ratio tended to decrease (1.2 [plusmn] 0.3 to 1.1 [plusmn] 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.</description><identifier>ISSN: 0026-0495</identifier><identifier>EISSN: 1532-8600</identifier><identifier>DOI: 10.1053/meta.2002.30506</identifier><identifier>PMID: 11887166</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adiponectin ; Adipose Tissue - pathology ; Adult ; Asian Continental Ancestry Group ; Biological and medical sciences ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - ethnology ; Diabetes Mellitus, Type 2 - pathology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Humans ; Hypoglycemic Agents - therapeutic use ; Intercellular Signaling Peptides and Proteins ; Japan ; Male ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Pioglitazone ; Proteins - analysis ; Thiazoles - therapeutic use ; Thiazolidinediones ; Time Factors</subject><ispartof>Metabolism, clinical and experimental, 2002-03, Vol.51 (3), p.314-317</ispartof><rights>2002</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 by W.B. Saunders Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-ca412a2279fb205235fd0bf10db06620fa37a50d2db5b864a0b67ab4d385824e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/meta.2002.30506$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13534307$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11887166$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirose, Hiroshi</creatorcontrib><creatorcontrib>Kawai, Toshihide</creatorcontrib><creatorcontrib>Yamamoto, Yukihiro</creatorcontrib><creatorcontrib>Taniyama, Matsuo</creatorcontrib><creatorcontrib>Tomita, Motowo</creatorcontrib><creatorcontrib>Matsubara, Koichi</creatorcontrib><creatorcontrib>Okazaki, Yasunori</creatorcontrib><creatorcontrib>Ishii, Tatsuya</creatorcontrib><creatorcontrib>Oguma, Yuko</creatorcontrib><creatorcontrib>Takei, Izumi</creatorcontrib><creatorcontrib>Saruta, Takao</creatorcontrib><title>Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes</title><title>Metabolism, clinical and experimental</title><addtitle>Metabolism</addtitle><description>The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 [plusmn] 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 [plusmn] 14 to 101 [plusmn] 10 mm Hg), FPG (8.6 [plusmn] 1.4 to 7.0 [plusmn] 1.0 mmol/L), serum insulin (54 [plusmn] 11 to 30 [plusmn] 8 pmol/L, P [lt ] .01 for all), and HbA1c (6.7 [plusmn] 0.8 to 6.1% [plusmn] 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 [plusmn] 3.2 to 27.0 [plusmn] 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 [plusmn] 24 to 138 [plusmn] 24 mg/dL) and SAT (155 [plusmn] 69 to 179 [plusmn] 81cm2, P [lt ] .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 [plusmn] 1.7 to 14.4 [plusmn] 2.1 [mu ]g/mL, P = .005). VAT tended to increase (165 [plusmn] 38 to 180 [plusmn] 46 cm2) and VAT/SAT ratio tended to decrease (1.2 [plusmn] 0.3 to 1.1 [plusmn] 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.</description><subject>Adiponectin</subject><subject>Adipose Tissue - pathology</subject><subject>Adult</subject><subject>Asian Continental Ancestry Group</subject><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - ethnology</subject><subject>Diabetes Mellitus, Type 2 - pathology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Intercellular Signaling Peptides and Proteins</subject><subject>Japan</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Pioglitazone</subject><subject>Proteins - analysis</subject><subject>Thiazoles - therapeutic use</subject><subject>Thiazolidinediones</subject><subject>Time Factors</subject><issn>0026-0495</issn><issn>1532-8600</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhi0EokvhzA35AqdmO7HjfBxRVb5UiQuco7E9BqMkDrZTtPwN_jBedqWeONkePX5m9A5jL2vY16Dk9UwZ9wJA7CUoaB-xXa2kqPoW4DHblXpbQTOoC_YspR8A0HV9-5Rd1HXfd3Xb7tifW-fI5MSD46sP3yaf8XdYiIeFH-U6TN7wFSOWF8V0xXWwB-4wc-tTjl5v2YfliuNieaK4zRytX4vBZL_wie5pSrzcPuGKCyXiM05UhNnTUtr-8vk7z4eVuChC1KVJes6eOJwSvTifl-zru9svNx-qu8_vP968vauM7GSuDDa1QCG6wWkBSkjlLGhXg9XQtgIcyg4VWGG10n3bIOi2Q91Y2ateNCQv2ZuTd43h50Ypj7NPhqapDBq2NHa1ggHUUMDrE2hiSCmSG9foZ4yHsYbxuIfxGNV43MP4bw_lx6uzetMz2Qf-HHwBXp8BTAYnF3ExPj1wUslGQle44cSVGOneUxyTKckZsj6WiEcb_H-H-AsK9Kaq</recordid><startdate>20020301</startdate><enddate>20020301</enddate><creator>Hirose, Hiroshi</creator><creator>Kawai, Toshihide</creator><creator>Yamamoto, Yukihiro</creator><creator>Taniyama, Matsuo</creator><creator>Tomita, Motowo</creator><creator>Matsubara, Koichi</creator><creator>Okazaki, Yasunori</creator><creator>Ishii, Tatsuya</creator><creator>Oguma, Yuko</creator><creator>Takei, Izumi</creator><creator>Saruta, Takao</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020301</creationdate><title>Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes</title><author>Hirose, Hiroshi ; Kawai, Toshihide ; Yamamoto, Yukihiro ; Taniyama, Matsuo ; Tomita, Motowo ; Matsubara, Koichi ; Okazaki, Yasunori ; Ishii, Tatsuya ; Oguma, Yuko ; Takei, Izumi ; Saruta, Takao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-ca412a2279fb205235fd0bf10db06620fa37a50d2db5b864a0b67ab4d385824e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adiponectin</topic><topic>Adipose Tissue - pathology</topic><topic>Adult</topic><topic>Asian Continental Ancestry Group</topic><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - ethnology</topic><topic>Diabetes Mellitus, Type 2 - pathology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Intercellular Signaling Peptides and Proteins</topic><topic>Japan</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Pioglitazone</topic><topic>Proteins - analysis</topic><topic>Thiazoles - therapeutic use</topic><topic>Thiazolidinediones</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirose, Hiroshi</creatorcontrib><creatorcontrib>Kawai, Toshihide</creatorcontrib><creatorcontrib>Yamamoto, Yukihiro</creatorcontrib><creatorcontrib>Taniyama, Matsuo</creatorcontrib><creatorcontrib>Tomita, Motowo</creatorcontrib><creatorcontrib>Matsubara, Koichi</creatorcontrib><creatorcontrib>Okazaki, Yasunori</creatorcontrib><creatorcontrib>Ishii, Tatsuya</creatorcontrib><creatorcontrib>Oguma, Yuko</creatorcontrib><creatorcontrib>Takei, Izumi</creatorcontrib><creatorcontrib>Saruta, Takao</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolism, clinical and experimental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirose, Hiroshi</au><au>Kawai, Toshihide</au><au>Yamamoto, Yukihiro</au><au>Taniyama, Matsuo</au><au>Tomita, Motowo</au><au>Matsubara, Koichi</au><au>Okazaki, Yasunori</au><au>Ishii, Tatsuya</au><au>Oguma, Yuko</au><au>Takei, Izumi</au><au>Saruta, Takao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes</atitle><jtitle>Metabolism, clinical and experimental</jtitle><addtitle>Metabolism</addtitle><date>2002-03-01</date><risdate>2002</risdate><volume>51</volume><issue>3</issue><spage>314</spage><epage>317</epage><pages>314-317</pages><issn>0026-0495</issn><eissn>1532-8600</eissn><abstract>The aim of this study was to evaluate the effects of pioglitazone on clinical and metabolic parameters, body fat distribution, and serum adiponectin, a recently discovered antiatherosclerotic hormone, in Japanese patients with type 2 diabetes. Ten male patients aged 40 to 66 (57.7 [plusmn] 7.4) years, who were being treated with dietary therapy alone (n = 7) or with a stable dose of sulfonylurea (n = 3), were studied at baseline and after 3 months of pioglitazone treatment (30 mg/d). Body mass index (BMI), blood pressure, fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), serum insulin, adiponectin, and lipid profile were measured. Also, visceral adipose tissue area (VAT) and subcutaneous adipose tissue area (SAT) at the umbilical level were determined by computed tomographic (CT) scanning. Mean blood pressure (109 [plusmn] 14 to 101 [plusmn] 10 mm Hg), FPG (8.6 [plusmn] 1.4 to 7.0 [plusmn] 1.0 mmol/L), serum insulin (54 [plusmn] 11 to 30 [plusmn] 8 pmol/L, P [lt ] .01 for all), and HbA1c (6.7 [plusmn] 0.8 to 6.1% [plusmn] 0.6%, P = .013) decreased significantly during 3 months of pioglitazone treatment. BMI (26.4 [plusmn] 3.2 to 27.0 [plusmn] 3.5 kg/m2), low-density lipoprotein (LDL) cholesterol (124 [plusmn] 24 to 138 [plusmn] 24 mg/dL) and SAT (155 [plusmn] 69 to 179 [plusmn] 81cm2, P [lt ] .05 for all) increased, while triglycerides and high-density lipoprotein (HDL) cholesterol did not change significantly after 3 months of pioglitazone treatment. Serum adiponectin level increased in all patients (4.8 [plusmn] 1.7 to 14.4 [plusmn] 2.1 [mu ]g/mL, P = .005). VAT tended to increase (165 [plusmn] 38 to 180 [plusmn] 46 cm2) and VAT/SAT ratio tended to decrease (1.2 [plusmn] 0.3 to 1.1 [plusmn] 0.3), but these differences did not reach statistical significance. These results suggest that pioglitazone exerts good glycemic and blood pressure control despite increased BMI and SAT in Japanese male patients with type 2 diabetes. It is also suggested that pioglitazone may have an antiatherosclerotic effect by increasing serum adiponectin level.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11887166</pmid><doi>10.1053/meta.2002.30506</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0026-0495 |
| ispartof | Metabolism, clinical and experimental, 2002-03, Vol.51 (3), p.314-317 |
| issn | 0026-0495 1532-8600 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71509059 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adiponectin Adipose Tissue - pathology Adult Asian Continental Ancestry Group Biological and medical sciences Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - ethnology Diabetes Mellitus, Type 2 - pathology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Humans Hypoglycemic Agents - therapeutic use Intercellular Signaling Peptides and Proteins Japan Male Medical sciences Metabolic diseases Middle Aged Obesity Pioglitazone Proteins - analysis Thiazoles - therapeutic use Thiazolidinediones Time Factors |
| title | Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T06%3A51%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20pioglitazone%20on%20metabolic%20parameters,%20body%20fat%20distribution,%20and%20serum%20adiponectin%20levels%20in%20Japanese%20male%20patients%20with%20type%202%20diabetes&rft.jtitle=Metabolism,%20clinical%20and%20experimental&rft.au=Hirose,%20Hiroshi&rft.date=2002-03-01&rft.volume=51&rft.issue=3&rft.spage=314&rft.epage=317&rft.pages=314-317&rft.issn=0026-0495&rft.eissn=1532-8600&rft_id=info:doi/10.1053/meta.2002.30506&rft_dat=%3Cproquest_cross%3E71509059%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71509059&rft_id=info:pmid/11887166&rft_els_id=S0026049502174385&rfr_iscdi=true |